UNUSUAL SITE THROMBOSIS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: THE EXPERIENCE WITH 66 CONSECUTIVE CASES.

EHA Library, Erika Morsia, 387295

COMORBIDITIES PREDICT WORSE PROGNOSIS IN PATIENTS WITH POLYCYTHEMIA VERA

EHA Library, Isidora Arsenovic, 387296

A RETROSPECTIVE MULTI-CENTER STUDY ON DIRECT ORAL ANTICOAGULANT USE IN BCR::ABL1 NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Mehmet Baysal, 387297

JAK2 V617F ALLELE BURDEN AND THROMBOTIC EVENTS IN PATIENTS WITH JAK2 V617F POSITIVE POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA AT HIGH RISK OF THROMBOSIS

EHA Library, Yun hui Hwang, 387298

JAK2 V617F MUTATION BURDEN DETECTION AND RELATIONSHIP WITH LABORATORY CHARACTERISTICS IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Xuefei Ma, 387299

HIGHER JAK2 ALLELE BURDEN IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS IS ASSOCIATED WITH HIGHER PREVALENCE OF CHRONIC KIDNEY DISEASE AND UNFAVORABLE DYNAMICS OF KIDNEY FUNCTION OVER TIME

EHA Library, Marko Lucijanic, 387300

CHARACTERISTICS OF PATIENTS WITH POLYCYTHEMIA VERA:  RESULTS FROM A US ELECTRONIC HEALTH RECORDS DATABASE.

EHA Library, Ronald Hoffman, 387301

CLINICAL IMPACT OF NUTRITIONAL STATUS AND NUTRITIONAL MONITORING IN PRIMARY MYELOFIBROSIS PATIENTS: PRELIMINARY RESULTS OF NUTRIMY STUDY

EHA Library, Margherita Malchiodi, 387302

ADULT LANGERHANS CELL HISTIOCYTOSIS WITH LIVER INVOLVEMENT

EHA Library, Long Chang, 387303

TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)

EHA Library, Francesca Palandri, 387304

GEOGRAPHIC CLUSTERING OF ERDHEIM-CHESTER DISEASE IN ITALY AND FRANCE

EHA Library, Francesco Peyronel, 387305

FOOD AND ACID REDUCING AGENT EFFECTS ON PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF THE COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) TL-895 IN HEALTHY SUBJECTS

EHA Library, Martine Allard, 387306

ASSOCIATION OF HIGH PLATELETCRIT WITH THROMBOTIC RISK IN POLYCYTHEMIA VERA DEPENDS ON HEMATOCRIT AND LEUKOCYTE COUNT

EHA Library, Ivan Krecak, 387307

NOVEL PREDICTORS FOR VENOUS AND ARTERIAL THROMBOSIS IN POLYCYTHEMIA VERA

EHA Library, Jelena Ivanović, 387308

INCIDENCE AND PREVALENCE OF MYELOFIBROSIS IN GERMANY: A RETROSPECTIVE CLAIMS DATA ANALYSIS

EHA Library, Sophia Junker, 387309

HIGH SERUM FERRITIN AT INITIAL DIAGNOSIS IS A PREDICTOR OF BONE MARROW FIBROSIS IN PH NEGATIVE  CHRONIC MYELOPROLIFERATIVE NEOPLASMS

EHA Library, ALDO LEONE, 387310

A MECHANISTIC ABSORPTION AND PHARMACOKINETIC MODEL OF COVALENT BTK INHIBITOR TL-895: INFLUENCE OF FOOD AND ACID REDUCING AGENTS

EHA Library, Martine Allard, 387311

PROGRESSION FACTORS OF MYELOFIBROSIS BASED ON CLINICAL FEATURES AND NEXT-GENERATION SEQUENCING LANDSCAPE OF ESSENTIAL THROMBOCYTHEMIA: A CHINES TWO-CENTER RETROSPECTIVE STUDY

EHA Library, JIAN HUANG, 387312

NEUTROPHIL–TO-LYMPHOCYTE RATIO IS AN EARLY SCREENING TOOL FOR DIAGNOSIS OF POLYCYTHEMIA VERA

EHA Library, Seug Yun Yoon, 387313

CLUSTER ANALYSIS UNVEILS THE CLINICAL SPECTRUM OF ERDHEIM-CHESTER DISEASE

EHA Library, Francesco Pegoraro, 387314

COMPARISON OF THREE PROGNOSTIC SCORING SYSTEMS FOR THE RISK OF THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA: ANALYSIS OF 190 PATIENTS AT THE UNIVERSITY HOSPITAL OF THE CANARY ISLANDS (1990-2022)

EHA Library, Marta Diaz-Lopez, 387315

DIFFERENCES IN POST-POLYCYTHEMIA VERA AND POST–ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS VS PRIMARY MYELOFIBROSIS IN FIBROTIC STAGE : A RETROSPECTIVE, REAL-WORLD STUDY CONDUCTED IN CHINA

EHA Library, JIAN HUANG, 387316

ABDOMINAL AORTIC CALCIFICATION IN PATIENTS NEWLY DIAGNOSED WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASM

EHA Library, Myung-Won Lee, 387317

RETROSPECTIVE ANALYSIS OF 45 UNSELECTED PATIENTS WITH HISTIOCYTOSIS CONFIRMS PROGNOSTIC RELEVANCE OF ORGAN INVOLVEMENT: SINGLE‐CENTER EXPERIENCE

EHA Library, Hulya Yilmaz, 387318

CORRELATION BETWEEN HEMORRHAGIC EVENTS AND IPSET SCORE IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA

EHA Library, Mario Tiribelli, 387319

HYDROXYUREA-INDUCED CUTANEUS ADVERSE EVENTS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA: A SINGLE-CENTER EXPERIENCE

EHA Library, AMAIA LOPEZ-PEÑA, 387320

REAL-WORLD RESEARCH OF CLINICAL AND HEMATOLOGIC NEOPLASMS RELATED GENETIC MUTATIONS IN 275 POLYCYTHEMIA VERA PATIENTS

EHA Library, JIAN HUANG, 387321

CHILDHOOD MYELPROLIFERATIVE NEOPLASMS; A SINGLE CENTER EXPERIENCE

EHA Library, Hasanein Ghali, 387322

POLYPHARMACY AND DRUG-TO-DRUG INTERACTIONS MAY HAVE A NEGATIVE EFFECT ON SURVIVAL IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Ivan Krecak, 387323

ATRIAL FIBRILLATION IS FREQUENT IN PATIENTS WITH MYELOFIBROSIS AND MIGHT BE SUB-OPTIMALLY TREATED

EHA Library, Marko Lucijanic, 387324

AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF

EHA Library, Andrew Kuykendall, 387325

DOES LUNG LESION SEVERITY AFFECT THE OUTCOME IN PEDIATRIC PULMONARY MULTISYSTEM LANGERHANS CELL HISTIOCYTOSIS ?

EHA Library, Mohamed Sedky Sedky, 387326

CLINICOPATHOLOGICAL, CYTOGENETIC AND MOLECULAR CHARACTERISTICS OF PATIENTS WITH NON-CML MYELOPROLIFERATIVE NEOPLASMS: A SINGLE CENTER STUDY

EHA Library, Vinay Anand Guntiboina, 387327

ABBV-744 ALONE OR IN COMBINATION WITH RUXOLITINIB OR NAVITOCLAX IN PATIENTS WITH MYELOFIBROSIS: A PHASE 1B STUDY

EHA Library, John Mascarenhas, 387328

A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF)

EHA Library, John Mascarenhas, 387329

HIGH RISK LANGERHANS CELL HISTIOCYTOSIS (LCH) IN CHILDREN: THE ROLE OF CLADRIBINE SALVAGE IN IMPROVING THE OUTCOME. A SINGLE CENTER EXPERIENCE

EHA Library, Mohamed Sedky Sedky, 387330

TRANSFORMATION OF MYELOPROLIFERATIVE NEOPLASMS INTO ACUTE PROMYELOCYTIC LEUKEMIA: SYSTEMATIC REVIEW AND META-ANALYSIS OF CASE REPORTS

EHA Library, Mihnea-Alexandru Găman, 387331

WHAT IS THE UTILITY OF THE MYSEC-PM ON SECONDARY MYELOFIBROSIS RISK STRATIFICATION IN A REAL LIFE SETTING?

EHA Library, Pedro Moura, 387332

A PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF BENRALIZUMAB IN PATIENTS WITH HYPEREOSINOPHILIC SYNDROME

EHA Library, Priya Jain, 387333

THE ORIGIN IN PRIMARY AND SECONDARY MYELOFIBROSIS: IS THE KEY THE PROGENITOR OR THE MOLECULAR SIGNATURE?

EHA Library, Isabel Montero, 387334

AN OVERLOOKED MIMIC? AUTOIMMUNE MYELOFIBROSIS - A SCOPING REVIEW OF THE LITERATURE

EHA Library, Yosef Joseph Rene Amel Riazat-Kesh, 387335

A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA

EHA Library, Melisa Palacio, 387336

EFFECT OF HYDROXYUREA ON INFLAMMATORY MARKERS IN PATIENTS WITH BCR-ABL NEGATIVE MYELOPROLIFERATIVE DISEASES

EHA Library, Istemi Serin, 387337

POPULATION BASED INCIDENCE OF ESSENTIAL THROMBOCYTHEMIA: AN ALBANIAN STUDY (2007-2021)

EHA Library, Adela Perolla, 387338

NON-THROMBOTIC INCREASED PORTAL VENOUS PRESSURE IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: IS IT JUST A HYPOTHESIS?

EHA Library, Istemi Serin, 387339

ATYPICAL CHRONIC MYELOID LEUKEMIA. CLINICAL AND MOLECULAR FEATURES. A SINGLE CENTER EXPERIENCE.

EHA Library, Javier Alberto Rojas Martínez, 387340

ACQUIRED VON WILLEBRAND DISEASE (AVWD) DIAGNOSTIC PROFILE IN MYELOPROLIFERATIVE NEOPLASIA (MN) PATIENTS IN WESTERN-ESTONIA

EHA Library, Ines Vaide, 387341

TREATMENT OUTCOME OF CHRONIC MYELOMONOCYTIC LEUKEMIA; A SINGLE CENTRE EXPERIENCE FROM PAKISTAN

EHA Library, Nida Anwar, 387342

THE VASCULAR RISK OF ESSENTIAL THROMBOCYTHEMIA AND RELIABILITY OF THROMBOTIC RISK ASSESSMENT SCORES

EHA Library, Arij Cheffai, 387343

ACUTE LYMPHOBLASTIC LEUKEMIA SECONDARY TO ESSENTIAL THROMBOCYTHEMIA: SYSTEMATIC REVIEW AND META-ANALYSIS OF CASE REPORTS

EHA Library, Mihnea-Alexandru Găman, 387344

ROSAI-DORFMAN DISEASE -A SINGLE CENTRE EXPERIENCE OF A RARE HISTIOCYTIC DISORDER

EHA Library, Sanjay Tewari, 387345

FEATURES OF POLYCYTHEMIA VERA WITH THE JAK 2 EXON 12 MUTATION.

EHA Library, Irina Soubortseva, 387346

POLYCYTHEMIA VERA (PV) AND SECONDARY POLYCYTHEMIA (SP): ARE METABOLIC DIFFERENCES JUST THEORIES?

EHA Library, Istemi Serin, 387347

BURDEN OF SYMPTOMS AND SYMPTOM EXPERIENCE OF FILIPINO MYELOPROLIFERATIVE NEOPLASM PATIENTS: A QUALITATIVE PHENOMENOLOGICAL STUDY

EHA Library, Flordeluna Mesina, 387349

BONE MARROW NECROSIS: RARE PRESENTATION OF CHRONIC MYELOID NEOPLASMS SYSTEMIC REVIEW AND CASE REPORT

EHA Library, Verna Cheung, 387350

ATYPICAL CHRONIC MYELOID LEUKEMIA (ACML) AND AUTOIMMUNE DISEASE: REPORT OF TWO CASES.

EHA Library, Caterina Tatarelli, 387351

THE IMPACT OF JAK2V617F MUTATION POSITIVITY IN ESSENTIAL THROMBOCYTHEMIA:ABOUT 74 CASES.

EHA Library, Arij Cheffai, 387352

SOMETIMES IT'S ZEBRAS: SUCCESSFUL TREATMENT OF ERYTHROPOIETIC PROTOPORPHYRIA POST PRIMARY MYELOFIBROSIS WITH GIVOSIRAN - A CASE REPORT

EHA Library, Alina Catana, 387353

A PATIENT WITH SEVERE APLASTIC ANEMIA UNDERWENT ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION. EVIDENCE-BASED NURSING CARE OF PATIENTS COMPLICATED WITH ORAL AND LABIAL TISSUE ULCERATION

EHA Library, Li Wang, 387354

HYPEREOSINOPHILIC SYNDROMES:   CARDIAC EMERGENCY IN THE ELDERLY

EHA Library, ahlam gougas, 387355

TREATMENT OUTCOME AND PROGNOSTIC FACTORS IN CHILDREN AND ADOLESCENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA

EHA Library, Nesreen Ali, 387356

ASSESSMENT OF CHEMOTHERAPY-INDUCED TOXICITY IN CHILDREN WITH HODGKIN LYMPHOMA RECEIVING THE EURONET PROTOCOL

EHA Library, Nesreen Ali, 387357

EPIDEMIOLOGY AND OUTCOMES OF HODGKIN LYMPHOMA IN URUGUAY. A NATIONAL REGISTRY

EHA Library, Carolina Oliver, 387358

OUTCOME AND PROGNOSTIC FACTORS OF PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA: A SINGLE-CENTER EXPERIENCE

EHA Library, Nesreen Ali, 387359

PHASE 1 FIRST IN HUMAN STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF GRC54276, A NOVEL HPK1 THRONINE-KINASE INHIBITOR, IN ADVANCED SOLID TUMOURS AND LYMPHOMAS.

EHA Library, Harsha Doddihal, 387360

THE NEW PD-1 INHIBITOR PROLGOLIMAB IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA

EHA Library, Anastasia SEMENOVA, 387361

FIVE-YEAR SINGLE-CENTER EXPERIENCE IN THE TREATMENT OF ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA WITH ABVD

EHA Library, Vojin Vukovic, 387362

DECREASE IN NEUTROPHIL-LYMPHOCYTE RATIO IMPACTS OVERALL SURVIVAL OF ADULT PATIENTS WITH HODGKIN LYMPHOMA AFTER ANTI-PD1 TREATMENT

EHA Library, Christos Varelas, 387363

PROGNOSTIC FACTORS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKINN LYMPHOMA

EHA Library, kmira zahra, 387364

TOXICITY PROFILE OF SALVAGE CHEMOTHERAPY REGIMENS IN PATIENTS WITH RELAPSED / REFRACTORY HODGKIN LYMPHOMA.

EHA Library, kmira zahra, 387365

CLINICAL FEATURES, TREATMENT PATTERNS, AND OUTCOMES AMONG 120 PATIENTS WITH MALT LYMPHOMA IN LATIN AMERICA: A STUDY FROM THE GRUPO DE ESTUDIO LATINOAMERICANO DE LINFOPROLIFERATIVOS (GELL)

EHA Library, Alana von Glasenapp, 387366

RISK FACTORS FOR DISEASE PROGRESSION OF MYCOSIS FUNGOIDES AND SÉZARY SYNDROME IN EAST ASIAN POPULATION

EHA Library, Huai-Chueh Gem Wu, 387367

TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5)

EHA Library, Umberto Vitolo, 387368

TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-1)

EHA Library, Stefano Luminari, 387369

PAX5 ABERRANT EXPRESSION INCORPORATED IN MIPI-SP RISK SCORING SYSTEM EXHIBITS ADDITIVE VALUE IN MANTLE CELL LYMPHOMA

EHA Library, Xin Zhang, 387370

PI3KΔ INHIBITOR LINPERLISIB FOR ELDERLY PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL

EHA Library, Xiuhua Sun, 387371

PROGNOSTIC VALUE OF INTERIM POSITRON EMISSION TOMOGRAPHY IN HIGH-TUMOR-BURDEN FOLLICULAR LYMPHOMA

EHA Library, Marta Mora Argumánez, 387372

ANALYSIS OF CLINICAL AND LABORATORY PARAMETERS IN PATIENTS WITH PRIMARY ORBITAL AND ADNEXAL MUCOSSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA- A TWENTY YEARS SINGLE CENTRE EXPERIENCE

EHA Library, Mihailo Smiljanic, 387373

PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL

EHA Library, Lihua Qiu, 387374

EFFICACY OF OBINUTUZUMAB - BASED REGIMENS IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RETROSPECTIVE OBSERVATIONAL SINGLE-CENTER STUDY

EHA Library, Nevenka Ridova, 387375

REAL-WORLD OUTCOME OF FOLLICULAR LYMPHOMA IN TAIWAN: A MULTICENTER REGISTRY STUDY

EHA Library, Bor-Sheng Ko, 387376

TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2)

EHA Library, Silvana Novelli, 387377

MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA

EHA Library, Antonio Salar Silvestre, 387378

PROGNOSTIC SIGNIFICANCE OF SERUM MONOCLONAL PROTEINS BASED ON IMMUNOFIXATION ELECTROPHORESIS IN B CELL NON-HODGKIN LYMPHOMA

EHA Library, Yuyang Gao, 387379

ACQUIRED ANGIOEDEMA ASSOCIATED WITH LYMPHOPROLIFERATIVE DISORDERS: A CASE SERIES

EHA Library, Jun Yen Ng, 387380

TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY

EHA Library, Seok-Goo Cho, 387381

MULTISYSTEM ERDHEIM CHESTER NEOPLASM WITH BRAFV660E MUTATION, PROMINENT EMPERIPOLESIS, HEMOPHAGOCYTOSIS AND FULMINANT COURSE

EHA Library, Dina Soliman, 387382

TRIAL IN PROGRESS: FOLLICULAR LYMPHOMA OUTCOMES IN RELAPSED/REFRACTORY PATIENTS TREATED WITH SYSTEMIC THERAPY IN A REAL-WORLD ASSESSMENT (FLORA)

EHA Library, Gandhi Laurent Damaj, 387383

MEK-KINASE INHIBITOR (TRAMETINIB) AS A TREATMENT OPTION FOR HAIRY CELL LEUKEMIA

EHA Library, Lyubov Al-Radi, 387384

IN THE ERA OF IMMUNOPHENOTYPING AND MOLECULAR DIAGNOSTICS DOES MORPHOLOGY PLAY AN ESSENTIAL ROLE IN DIFFERENTIATING HAIRY CELL LEUKEMIA FROM ITS MIMICS?

EHA Library, Priyavadhana Balasubramanian, 387385

EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC ASPECT OF INDOLENT LYMPHOMAS IN TUNISIA

EHA Library, ons charef, 387386

DIVERSITY OF IGG4-RELATED DISEASE : A CASE SERIES OF FOUR PATIENTS

EHA Library, Hind Hanani, 387387

EVALUATION OF THE THERAPEUTIC RESULTS OF LYMPHOBLASTIC LYMPHOMA TREATED ACCORDING TO THE EORTC 58951 PROTOCOL IN CHILDREN ADOLESCENTS AND YOUNG ADULTS

EHA Library, Hana BEN HAMMAMIA, 387388

INCIDENCE OF NEWLY DIAGNOSED AGGRESSIVE NON-HODGKIN'S LYMPHOMA BEFORE AND DURING THE COVID-19 PANDEMIC IN ISRAEL - A SINGLE CENTER RETROSPECTIVE STUDY

EHA Library, Yotam Bronstein, 387390

PRELIMINARY DATA FROM A FIRST-IN HUMAN PHASE II STUDY OF SEQUENTIAL USE OF SELINEXOR AND CD19 CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELL THERAPY (CART19) IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

EHA Library, Caixia Li, 387391

IMPACT OF RESOURCE AVAILABILITY ON OUTCOMES OF DIFFUSE LARGE B-CELL LYMPHOMA IN PAKISTAN: A DEVELOPING COUNTRY EXPERIENCE

EHA Library, Raheel Iftikhar, 387392

EFFICACY OF SPLENECTOMY IN SPLENIC MARGINAL ZONE LYMPHOMA

EHA Library, Yuriy Yevstakhevych, 387393

DEVELOPMENT OF CARDIOTOXICITY NEGATIVELY IMPACTS IN OVERALL SURVIVAL IN PATIENTS WITH LYMPHOMA TREATED WITH FIRST-LINE ANTHRACYCLINES

EHA Library, Alberto López García, 387394

REAL WORLD STUDY OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN THE ELDERLY: FOURTEEN YEARS OF ONE CENTER'S EXPERIENCE

EHA Library, Victoria Ramos De Ascanio, 387395

DOSE-ADJUSTED EDOCH AS FIRST-LINE THERAPY IMPROVED PROGNOSIS OF ADULT T-CELL LEUKEMIA/LYMPHOMA: A 11-YEAR MULTICENTER RETROSPECTIVE STUDY IN CHINA

EHA Library, Jianda Hu, 387396